Product Update

botulinum toxin type A, 50 and 100 LD₅₀ units powder for solution for injection (Xeomin®) (No: 731/11)
Merz Pharma UK Ltd

09 September 2011

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

botulinum toxin type A (Xeomin®) is accepted for use within NHS Scotland.

Indication under review: post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.

In patients for whom botulinum toxin, type A is an appropriate choice of therapy, this offers an alternative formulation to the comparator product containing conventional botulinum toxin, type A complex.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 19 May 2011.

Chairman,
Scottish Medicines Consortium